Price T Rowe Associates Inc Akero Therapeutics, Inc. Transaction History
Price T Rowe Associates Inc
- $812 Billion
- Q1 2025
A detailed history of Price T Rowe Associates Inc transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 4,817,091 shares of AKRO stock, worth $223 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
4,817,091
Previous 4,321,972
11.46%
Holding current value
$223 Million
Previous $120 Million
62.18%
% of portfolio
0.02%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding AKRO
# of Institutions
270Shares Held
86MCall Options Held
1.02MPut Options Held
823K-
Rtw Investments, LP New York, NY7.42MShares$344 Million4.92% of portfolio
-
Janus Henderson Group PLC London, X07.07MShares$328 Million0.16% of portfolio
-
Wellington Management Group LLP Boston, MA5.94MShares$275 Million0.05% of portfolio
-
Black Rock Inc. New York, NY5.59MShares$259 Million0.0% of portfolio
-
General Atlantic LLC New York, NY5.23MShares$243 Million7.15% of portfolio
About Akero Therapeutics, Inc.
- Ticker AKRO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,417,600
- Market Cap $2.15B
- Description
- Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...